

**EuroThrombosis Summit 2009,
October 8.–10. Oslo, Norway**

Preliminary Program

(December 2008)

ORGANIZING COMMITTEE

H. Arnesen
I. Seljeflot
K. Huber
F. Andreotti
S. Dalby Kristensen
F.W.A. Verheugt
K. Fox
L. Badimon
R. De Caterina
D. Gulba
G. Steg



CONGRESS & EVENT ORGANIZERS

Nina Wahlstrøm Krogstad
Tel: +47 905 45 905
Mail: nina@osi.ac

Sidsel Grepstad Dalaker
Tel: +47 928 21 215
Mail: sid-da@online.no

Thursday 08.10.08

1700-1800 Registration

Satellite /Special Symposium (Sponsored)

1800-2000

A survey on anti-thrombotics in CAD

Chairs: I.Seljeftot, Oslo (N) / F.Andreotti, Rome (IT)

Anticoagulants

F.Verheugt, Nijmegen (NL)

Antiplatelets

R. De Caterina, Chieti (IT)

Where to go?

L.Wallentin, Uppsala (S)

Between bench and bedside; Clinical research with anti-thrombotics

H.Arnese, Oslo (N)

2000

Get together party

Friday 09.10.09

Scientific Sessions

0830 Registration

0900 The ESC Working Group on Thrombosis: mission and activities
F.Andreotti, Rome (IT) (Chair of the WG18)

0915 **Symposia**

0915-1100

Atherothrombosis in diabetes – special reference to AMI

Chairs: H.Arnese, Oslo (N) / R.De Caterina, Chieti (IT)

Overview: Atherothrombosis in diabetes

T. Wascher, Vienna (A)

Diagnosis of diabetes and abnormal glucose tolerance in AMI: Status

G.Ø. Andersen, Oslo (N)

The GLUMIK-study: Glucometabolic state in STEMI

E.C. Knudsen, Oslo (N)

Tissue factor and TFPI in diabetes with CAD

T.O. Andersen, Oslo (N)

The role of C-peptide in diabetes with CAD

N.Marx, Ulm (D)

Adipose tissue and METS

Thomas Weiss, Oslo (N)/Vienna (A)

Friday cont.

1100-1130 *Coffee break*

Parallell sessions

1130-1300 Arterial thrombosis during dual antiplatelet therapy

Chairs: TBA / H.Arnese, Oslo (N)
Mechanisms on thrombus formation. Updated view
L. Badimon, Barcelona (ES)
Mural thrombosis in AMI
S. Solheim, Oslo (N)
Late stent thrombosis
F.-J. Neumann, Bad Krozingen (DE)?
Up-date on new stents
D. Gulba, Düren (D)

1130-1300 Clinical problems in ACS;

In collaboration with WG Acute Coronary Care

Chairs: S.D. Kristensen, Århus (DK) / N. Danchin, Paris (F)
Which drugs in the ambulance for ACS?
C. Vrints, Antwerpen (B)?
Antithrombotic and antiplatelet therapy with primary PCI
D. Dudek, Krakow (P)?
Challenges in the combination of antithrombotic and antiplatelet therapies in ACS
M. Valgimigli, Ferrara (IT)?
Net clinical benefit in ACS
P. Clemmensen, Århus (DK)?

1300-1430 Lunch break (evt. with Poster session)

1430-1515 Non-responsiveness to antiplatelets

Chairs: I. Seljeflot, Oslo (N) / S. D. Kristensen, Århus (DK)
Overview
M. Cattaneo, Milan (IT)
Aspirin non-responsiveness and Clopidogrel End-point Trial (ASCET):
Status
A-Å. Pettersen, Oslo (N)
Danish Aspirin Resistance Trial (DANART): Sub-studies
E.C.L. Grove, Århus (DK)
Clopidogrel non-responsiveness
J-P. Collet, Paris (F)?

1515-1530 *Coffee break*

Friday cont.

Parallell sessions

- 1530-1630 Atrial fibrillation – a prothrombotic state**
Chairs: P.Smith, Oslo (N) / K.Huber, Vienna (A)
Pathophysiology and risk for stroke
G.Lip, Birmingham (UK)?
PAI-1 prediction for relapse of AF post cardioversion
A.Tveit, Oslo (N)
Anticoagulation in AF: Status
H. Darius, Berlin (DE)?
- 1630-1645** Late news
TBA
- 1530-1700 Clinical issues in thrombosis;**
In collaboration with WG Acute Coronary Care
Chairs: KK Fox, Edinburgh (UK) / Y.Hasin, Poriya (Israel)?
Peri-operative management of antithrombotic therapy
A.Parkhomenko, Kiev (Ukraine)?
Prophylaxis and treatment of venous thromboembolism
H. Bounameaux, Geneva (CH)?
Ischaemic stroke: thrombolytic, antithrombotic and antiplatelet therapy
G.F. Gensini, Florence (IT)?
Antiplatelet therapy and DES: critical issues
P.G.Steg, Paris (F)
- 1645-1715 *Coffee break*
- 1715-1900 Satellite Symposium (sponsored)**
Chairs: L.Hvilsted Rasmussen, Ålborg (DK) / A.Siegbahn, Uppsala (S)
- The 110-year history of Aspirin**
C.Patrono, Rome (IT)
- New antiplatelet drugs in CAD**
Platelet physiology / activation: Overview with clinical relevance
K.Schrör, Düsseldorf (DE)
Prasugrel
S.D. Kristensen (DK)
Ticagrelor
L.Wallentin, Uppsala (S)
PAR-1 inhibitors
R.Storey, Sheffield (F)?
- 1930 Departure for dinner
- 2000 - Dinner party**

Saturday 10.10.09

0830

Symposia

0830-0945

Prehospital thrombolysis in STEMI

Chair: S.Halvorsen, Oslo / F.Verheugt, Niemegen (NL)

Status – with special reference to geographical challenges

F.van de Werf, Leuven (B)?

NORDISTEMI: Status / results

E.Bøhmer, Lillehammer (N)

Other ongoing trials

G.Steg, Paris (F)

STEMI-“loop” – up-date

K.Huber, Vienna (A)

0945-1030

Bleeding in ACS

Chair: F.Andreotti, Rome (IT) / J.Eritsland, Oslo (N)

Up-date

G.Steg, Paris (F)

Deaths from thrombo-embolism: Hypercoagulability –
platelet/monocyte complexes

A.Siegbahn, Uppsala (S)

Definition of bleeding

R.Storey, Sheffield (UK)?

MACE – including major bleeding

K.A.A.Fox, Edinburgh (GB)

1030-1100

Coffee break

1100-1145

Oral anticoagulants in heart failure

Chair: D.Atar, Oslo (N) / J.Morais, Leiria (P)

Antithrombotic treatment in HF; an overview

F.Andreotti, Rome (IT)

Ongoing clinical trials and future perspectives

J.G.B. Cleland, Hull (UK)?

1145-1245

Up-date in stem-cell therapy in MI

Chairs: S.D. Kristensen, Århus (DK) / F.J.Neuman, Bad Krozinger (DE)

Overview

J.F.Martin, London (UK)?

Adipocytes as stem-cell source

R.De Caterina, Chieti (IT)

Ongoing trials in MI

S.Solheim, Oslo (N)

Saturday cont.

1245-1315

“Pleiotropic effects of statins” – existing?

Chair: T.Pedersen, Oslo (N) / TBA

Focusing the link between lipids – coagulation – inflammation

J.Wojta, Vienna (A)

No:

Anton FH. Stalenhoef, Nijmegen (NL)

Yes:

C.Kluft, Sassenheim (NL)

1315-1500

Satellite Symposium (with lunch - Sponsored)

New anticoagulants in CAD

Chairs: K.A.A.Fox.W Edinburgh (GB) / L.Badimon, Barcelona (ES)

Inhibition of blood coagulation: Overview with clinical relevance

H.Arnese, Oslo (N)

FXa-inhibitors: ACS

K.Huber, Vienna (A)

FXa-inhibitors: Long-term

S.Husted, Århus (DK)

FIIa-inhibitors: ACS

L.Hvilsted-Rasmussen, Ålborg (DK)

FIIa-inhibitors: Long-term

F.Verheugt, Nijmegen (NL)

1500:

Closing remarks